Outsmarting cancer, together

Omico is a nationwide network of research and treatment centres that facilitates, supports and promotes clinical trials in genomic cancer medicine. Central to this is the use of molecular screening for the prevention and treatment of cancer.

Learn more

Our Vision

Omico will improve outcomes for Australians with cancer by accelerating the use of precision oncology as a research-led model of care, growing the clinical trials industry and modernising the Australian healthcare system.

Our Values

Innovation, Collaboration, and Hope

Our Mission

Masterclass Series

A series of 4 webinars over 4 weeks.

Webinar 1 – “Molecular pathology in cancer genomics, from sequencer to variant interpretation” delivered Thursday 29th October 2020 – access webinar 1 recording here

Webinar 2 –  “Translating genomic findings into treatment recommendations” delivered Thursday 5th November – access webinar 2 recording here

Webinar 3 –  “Germline Implications” delivered Thursday 12th November – access webinar 3 here

Webinar 4 –  “Live MTB meeting” delivered Thursday 19th November recording still to come

Recent News

Making a difference

3000 patients enrolled onto the Molecular Screening and Therapeutics (MoST) program, 1000 people have enrolled in the Genetic Cancer Risk in the Young (RisC) study and 95 people have joined the Surveillance study in Multi-Organ Cancer prone syndromes (SMOC+) - great news for cancer research.

Read more

Masterclass webinar series - Demystifying the Molecular Tumour Board

Learn how members of a Molecular Tumour Board (MTB) come together to discuss and interpret tumour molecular profiles in the clinical context, recommending therapeutic strategies for the care of patients with cancer. 4 webinars on 29th Oct, 5th, 12th and 19th Nov 2020, 4 - 5pm

Read more

How cancer develops resistance to treatment

The cells of the human body are constantly dividing, and each time need to copy a three billion-letter DNA code with high precision to ensure cell survival. The same is not true for cancers, researchers have discovered.

Read more
More news

Interested in knowing more?

Get in touch